AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23517050 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training program for emergency obstetric and perinatal care
Number of subjects: 15
Study 23517050 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased participation of professional midwives to strengthen the link between traditional birth attendants and the formal health care system
Number of subjects: 15
Study 23517050 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing campaign to promote institution-based deliveries
Number of subjects: 15
Study 23517050 — intervention group
Group type: COMPARATOR
Intervention: No external intervention planned for control clinics
Number of subjects: 15
Study 20567002 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prophylactic granulocyte colony-stimulating factor (PPGCSF)
Number of subjects: 239
Study 17588824 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention promoting healthy eating habits and increasing physical activity (n=153).
Number of subjects: 303
Study 17588824 — intervention group
Group type: COMPARATOR
Intervention: Alternative intervention promoting general self-esteem and social efficacy (n=150).
Number of subjects: 303
Study 16161730 — intervention group
Group type: EXPERIMENTAL
Intervention: Washington State Parent‐Child Assistance Program (intervention)
Number of subjects: 216
Study 16161730 — intervention group
Group type: COMPARATOR
Intervention: Control group (original demonstration)
Number of subjects: 216
Study 14633521 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 21
Study 14633521 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 21
Study 10705164 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective reminding procedure (SRP)
Number of subjects: 256
Study 10705164 — intervention group
Group type: COMPARATOR
Intervention: MMSE
Number of subjects: 256
Study 9234028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (60 g breakfast cereal daily with semi-skimmed milk)
Number of subjects: 59
Study 9234028 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 8383096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg daily for 7 days
Number of subjects: 100
Study 8383096 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg orally, or clotrimazole 200 mg intravaginally, twice weekly for six months
Number of subjects: 100
Study 3770039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine (Moniarix)
Number of subjects: 47
Study 3770039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30497534 — intervention group
Group type: EXPERIMENTAL
Intervention: KSR cultivation in Dong villages
Number of subjects: 156
Study 30497534 — intervention group
Group type: EXPERIMENTAL
Intervention: KSR cultivation area in Congjiang
Number of subjects: 156
Study 30497534 — intervention group
Group type: EXPERIMENTAL
Intervention: Farmers' attitudes towards KSR
Number of subjects: 156
Study 27089207 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 24
Study 27089207 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 24
Study 22948250 — intervention group
Group type: EXPERIMENTAL
Intervention: UHF rTMS (30 Hz)
Number of subjects: 43
Study 22948250 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 43
Study 20097417 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided treatment
Number of subjects: 626
Study 20097417 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard antibiotic treatment)
Number of subjects: 626
Study 18607265 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula (group A)
Number of subjects: 60
Study 18607265 — intervention group
Group type: COMPARATOR
Intervention: 5 g of rice cereal added to 100 mL standard formula (group B)
Number of subjects: 60
Study 18607265 — intervention group
Group type: COMPARATOR
Intervention: Formula manufactured with bean gum as a thickening agent (group C)
Number of subjects: 60
Study 15839182 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive diabetes care measures (1999-2001)
Number of subjects: 174
Study 15839182 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c testing
Number of subjects: 174
Study 15839182 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol testing
Number of subjects: 174
Study 15839182 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye examinations
Number of subjects: 174
Study 15839182 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol control
Number of subjects: 174
Study 15839182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephropathy monitoring
Number of subjects: 174
Study 12429196 — intervention group
Group type: COMPARATOR
Intervention: Parkinson's disease (PD)
Number of subjects: 60
Study 12429196 — intervention group
Group type: COMPARATOR
Intervention: Amyotrophic lateral sclerosis (ALS)
Number of subjects: 60
Study 12429196 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of PD and ALS
Number of subjects: 60
Study 10918827 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in a stroke unit
Number of subjects: 1241
Study 10918827 — intervention group
Group type: COMPARATOR
Intervention: General neurological/medical ward
Number of subjects: 1241
Study 8878223 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg once daily for 3 days)
Number of subjects: 343
Study 8878223 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (three times daily for 10 days)
Number of subjects: 343
Study 1457110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow at N2O 1 L/min and O2 0.6 L/min (Group 1)
Number of subjects: 36
Study 1457110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow at N2O 0.5 L/min and O2 0.5 L/min (Group 2)
Number of subjects: 36
Study 1457110 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate surplus of N2O and O2 with respect to the patient's O2 consumption (Group 3)
Number of subjects: 36
Study 3888246 — intervention group
Group type: COMPARATOR
Intervention: Local methoxsalen (13 cases)
Number of subjects: 84
Study 3888246 — intervention group
Group type: COMPARATOR
Intervention: Etretinate (20 cases)
Number of subjects: 84
Study 3888246 — intervention group
Group type: COMPARATOR
Intervention: Oral methoxsalen (13 cases)
Number of subjects: 84
Study 3888246 — intervention group
Group type: COMPARATOR
Intervention: 1% methoxsalen cream (33 cases)
Number of subjects: 84
Study 3888246 — intervention group
Group type: COMPARATOR
Intervention: Trioxsalen baths (18 cases)
Number of subjects: 84
Study 31861038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cannula
Number of subjects: 71
Study 31861038 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle
Number of subjects: 71
Study 29399799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous plus intra-articular tranexamic acid (20 mg/kg intravenous and 3.0 g intra-articular)
Number of subjects: 96
Study 29399799 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular tranexamic acid alone (3.0 g intra-articular and normal saline intravenous)
Number of subjects: 96
Study 29399799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous plus intra-articular tranexamic acid
Number of subjects: 96
Study 27457721 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological skills training (PST)
Number of subjects: 0
Study 27457721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MI)
Number of subjects: 0
Study 27457721 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 23200161 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect
Number of subjects: 1375
Study 23200161 — intervention group
Group type: COMPARATOR
Intervention: Control (low positive affect)
Number of subjects: 1375
Study 21844506 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN)
Number of subjects: 96
Study 21844506 — intervention group
Group type: COMPARATOR
Intervention: Conventional pain management
Number of subjects: 96
Study 19575807 — intervention group
Group type: COMPARATOR
Intervention: Post-program group (multidisciplinary breast cancer care units)
Number of subjects: 41833
Study 19575807 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (after invitation to screening)
Number of subjects: 41833
Study 19575807 — intervention group
Group type: COMPARATOR
Intervention: Pre-program group (before mammography screening)
Number of subjects: 41833
Study 19575807 — intervention group
Group type: COMPARATOR
Intervention: Post-program group vs Pre-program group
Number of subjects: 41833
Study 17074952 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual plus contingency management
Number of subjects: 113
Study 17074952 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 113
Study 15284214 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 1 mg + Dydrogesterone 5 mg (group D)
Number of subjects: 38
Study 15284214 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 1 mg + Norethisterone 0.5 mg (group N)
Number of subjects: 38
Study 11716200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose (doses ranging from 6.25 mg to 100 mg)
Number of subjects: 19
Study 11716200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11716200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose (higher than normal clinical doses)
Number of subjects: 19
Study 9158265 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-134a beclomethasone dipropionate (HFA-BDP)
Number of subjects: 68
Study 9158265 — intervention group
Group type: COMPARATOR
Intervention: CFC-beclomethasone dipropionate (CFC-BDP)
Number of subjects: 68
Study 7970121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal urokinase
Number of subjects: 24
Study 7970121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24
Study 2852903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg
Number of subjects: 14
Study 2852903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2 mg
Number of subjects: 14
Study 2852903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30734583 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 32
Study 30734583 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 32
Study 29358418 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-aid app
Number of subjects: 684
Study 29358418 — intervention group
Group type: COMPARATOR
Intervention: Information-only app
Number of subjects: 684
Study 27694489 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition plus exercise group
Number of subjects: 92
Study 27694489 — intervention group
Group type: COMPARATOR
Intervention: Nutrition group
Number of subjects: 92
Study 27694489 — intervention group
Group type: COMPARATOR
Intervention: Exercise group
Number of subjects: 92
Study 27694489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 27694489 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 92
Study 22943662 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day ketoprofen
Number of subjects: 409
Study 22943662 — intervention group
Group type: COMPARATOR
Intervention: 300 mg/day ketoprofen
Number of subjects: 409
Study 24301242 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone spray 0.25% twice daily
Number of subjects: 0
Study 24301242 — intervention group
Group type: COMPARATOR
Intervention: Vehicle spray twice daily
Number of subjects: 0
Study 20598972 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic health survey only (n = 865)
Number of subjects: 7687
Study 20598972 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard risk assessment (Framingham only) (n = 718)
Number of subjects: 7687
Study 20598972 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive risk assessment in a dedicated mobile facility (n = 6,104)
Number of subjects: 7687
Study 20598972 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced imaging with contrast-enhanced MRI and CT
Number of subjects: 7687
Study 18223492 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation in PBC patients
Number of subjects: 118
Study 18223492 — intervention group
Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 118
Study 20102775 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet I (low fat)
Number of subjects: 248
Study 20102775 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet II (low carbohydrate)
Number of subjects: 248
Study 16282177 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 258
Study 16282177 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 258
Study 12166347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen up to 1200 mg daily for 1-7 days
Number of subjects: 8633
Study 12166347 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol up to 3000 mg daily for 1-7 days
Number of subjects: 8633
Study 12166347 — intervention group
Group type: COMPARATOR
Intervention: Aspirin up to 3000 mg daily for 1-7 days
Number of subjects: 8633
Study 12166347 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of non-ulcer GI disease (n = 371)
Number of subjects: 8633
Study 12166347 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 8633
Study 9829540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribozyme transduced cells
Number of subjects: 0
Study 9829540 — intervention group
Group type: COMPARATOR
Intervention: Control murine retroviral vectors
Number of subjects: 0
Study 7988577 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of 0.083 mg ml-1 of diamorphine in 0.167% bupivacaine
Number of subjects: 40
Study 7988577 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of 0.083 mg ml-1 of diamorphine in 0.9% NaCl solution (control)
Number of subjects: 40
Study 2925353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (2 mg, oral administration)
Number of subjects: 20
Study 2925353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11695211 — intervention group
Group type: EXPERIMENTAL
Intervention: New dentifrice formulation variant (Colgate Total Plus Whitening Toothpaste)
Number of subjects: 97
Study 11695211 — intervention group
Group type: COMPARATOR
Intervention: Colgate Total Toothpaste
Number of subjects: 97
Study 29198062 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus of tinzaparin at the start of haemodialysis
Number of subjects: 23
Study 29198062 — intervention group
Group type: COMPARATOR
Intervention: Heparin in saline (H)
Number of subjects: 23
Study 29198062 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and albumin in saline (HA)
Number of subjects: 23
Study 29198062 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and albumin in combination with a citrate-containing dialysate (HAC)
Number of subjects: 23
Study 29198062 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline and using heparin-coated filters (Evodial®)
Number of subjects: 23
Study 27210854 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual percussion during postural drainage (PD) of the lower lobe
Number of subjects: 26
Study 27210854 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual percussion during postural drainage (PD) of the upper lobe
Number of subjects: 26
Study 27210854 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual percussion during postural drainage (PD) of the middle lobe
Number of subjects: 26
Study 27210854 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual percussion during postural drainage (PD) of the upper and middle lobes
Number of subjects: 26
Study 25080293 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF1 titration
Number of subjects: 92
Study 25080293 — intervention group
Group type: COMPARATOR
Intervention: High dose (67 μg/kg per day)
Number of subjects: 92
Study 25080293 — intervention group
Group type: COMPARATOR
Intervention: Low dose (35 μg/kg per day)
Number of subjects: 92
Study 22396129 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV31 A variants
Number of subjects: 470
Study 22396129 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV31 B variants
Number of subjects: 470
Study 22396129 — intervention group
Group type: COMPARATOR
Intervention: HPV31 C variants
Number of subjects: 470
Study 22396129 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV31 A variants (among women without CIN2/3 at first visit)
Number of subjects: 470
Study 22396129 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV31 B variants (among women without CIN2/3 at first visit)
Number of subjects: 470
Study 19141068 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 47
Study 19141068 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 47
Study 18525041 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg daily for 3 months, then 300 mg daily for 3 months)
Number of subjects: 599
Study 18525041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 599
Study 18525041 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 599
Study 18525041 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren and Placebo
Number of subjects: 599
Study 16005793 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer adhesive (Fuji Bond LC) combined with universal hybrid resin composite (Tetric Ceram)
Number of subjects: 73
Study 16005793 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer adhesive (Fuji Bond LC) combined with poly-acid modified resin composite (Hytac)
Number of subjects: 73
Study 16005793 — intervention group
Group type: COMPARATOR
Intervention: Sclerotic lesions
Number of subjects: 73
Study 16005793 — intervention group
Group type: COMPARATOR
Intervention: Non-sclerotic lesions
Number of subjects: 73
Study 12025250 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (12.5 mg)
Number of subjects: 90
Study 12025250 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine (12.5 mg)
Number of subjects: 90
Study 10496549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing speed tests (Trailmaking B and Cancellation Random Figure tests)
Number of subjects: 125
Study 10496549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive speed factor
Number of subjects: 125
Study 10496549 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and number of medications
Number of subjects: 125
Study 10496549 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Physical Performance Test (modified PPT)
Number of subjects: 125
Study 7724354 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 0
Study 7724354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7724354 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 2140554 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion (1.5 micrograms/Kg/min for 60 min)
Number of subjects: 20
Study 7004257 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered intravenous pethidine (0.25 mg/kg available at 10-min intervals)
Number of subjects: 0
Study 7004257 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine (150 mg, repeated if necessary)
Number of subjects: 0
Study 29463142 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM + emergency contraception (EC) group
Number of subjects: 200
Study 29463142 — intervention group
Group type: COMPARATOR
Intervention: LAM‐only group
Number of subjects: 200
Study 29152934 — intervention group
Group type: EXPERIMENTAL
Intervention: AuraGain™
Number of subjects: 98
Study 29152934 — intervention group
Group type: COMPARATOR
Intervention: LMA Protector™
Number of subjects: 98
Study 26863353 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab (10 mg daily)
Number of subjects: 75
Study 26863353 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 75
Study 26863353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 25002290 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (L‐T4) adjunctive treatment
Number of subjects: 20
Study 25002290 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 21422800 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE) during bed-rest
Number of subjects: 20
Study 21422800 — intervention group
Group type: COMPARATOR
Intervention: Inactive group (control)
Number of subjects: 20
Study 20561741 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 85
Study 20561741 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 85
Study 20561741 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 17323015 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk Walking (BW) at 6.2 ± 0.6 km/h for 30 minutes
Number of subjects: 14
Study 17323015 — intervention group
Group type: COMPARATOR
Intervention: Moderate Walking (MW) at 4.5 ± 0.6 km/h for 30 minutes
Number of subjects: 14
Study 17323015 — intervention group
Group type: COMPARATOR
Intervention: Control for both interventions (cTnT)
Number of subjects: 14
Study 17323015 — intervention group
Group type: COMPARATOR
Intervention: Control for both interventions (LV function)
Number of subjects: 14
Study 15750364 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologically targeted imagery (BTI)
Number of subjects: 70
Study 15750364 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical thinking asthma management (CTAM)
Number of subjects: 70
Study 15750364 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 70
Study 12172882 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity training (LEX)
Number of subjects: 62
Study 12172882 — intervention group
Group type: COMPARATOR
Intervention: High-intensity training (HEX)
Number of subjects: 62